Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)-Reference-Cited by-同舟云学术

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Published:2020-11-03 Issue:2 Volume:62 Page:368-376
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Coleman Morton¹,Belada David²,Casasnovas René-Olivier³,Gressin Rémy⁴⁵,Lee Hui-Peng⁶,Mehta Amitkumar⁷^ORCID,Munoz Javier⁸,Verhoef Gregor⁹,Corrado Claudia¹⁰,DeMarini Douglas J.¹⁰,Zhao Wanying¹⁰,Li Jia¹⁰,Fay Keith¹¹

Affiliation:

1. Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USA

2. 4th Department of Internal Medicine – Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic

3. University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France

4. Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France

5. Institute for Advanced Biosciences, Inserm U 823, Grenoble, France

6. Flinders Medical Centre, Bedford Park, SA, Australia

7. UAB School of Medicine, Birmingham, AL, USA

8. Banner MD Anderson Cancer Center, Gilbert, AZ, USA

9. Department of Hematology, University Hospitals Leuven, Leuven, Belgium

10. Incyte Corporation, Wilmington, DE, USA

11. Department of Haematology, St Vincent’s Hospital, Darlinghurst, NSW, Australia

Funder

Incyte Corporation

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1832660

Reference24 articles.

1. Diffuse large B-cell lymphoma

2. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

3. NCCN Guidelines® B-Cell Lymphomas Version 1.2020. U.S. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

4. Diffuse large B-cell lymphoma: R-CHOP failure—what to do?

5. The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

2. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study;Cancer Research Communications;2023-12-19

3. Small molecule inhibitors targeting regulatory T cells for cancer treatment;European Journal of Immunology;2023-11-15

4. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation;Hypertension;2023-04

5. Clinical Experience with Phosphatidylinositol 3‐Kinase Inhibitors in Hematologic Malignancies;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15